Turn on more accessible mode
Turn off more accessible mode
Sign In
Decrease
Normal
Increase
Contrast
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Yoav Shaul Lab
Faculty of Medicine New Site
The Faculty of Medicine
The Faculty of Medicine
Yoav Shaul Lab
Research
עברית
Yoav Shaul Lab
About the Lab
Research
Currently selected
Publications
Lab Staff
Lab Life
Contact Us
Main Item 1
Main Item 2
Main Item 3
Dropdown Level 1a
Dropdown Level 2 Label
Dropdown Level 2a
Dropdown Level 2b
Dropdown Level 2c
Dropdown Level 3 Label
Dropdown Level 3a
Dropdown Level 3b
Dropdown Level 3c
Dropdown Level 2d
Dropdown Level 2e
Dropdown Level 2f
Dropdown Level 1b
Dropdown Level 1c
Dropdown Level 1d
Dropdown Level 1e
Dropdown Level 1f
See all →
The truncated metabolic pathway model
In the “Coherent metabolic pathway”, all of the enzymes are co-expressed to successively generate series of reaction that leads to the end-products synthesis. In this pathway all of the intermediate molecules are short lived as they are catabolized by the downstream enzyme. In the “Truncated metabolic pathway” (lower panel), only the initial members of a given metabolic pathway are expressed giving a rise to the over-production of specific “immature” metabolites, designated “intermetabolites”. We proposed that these intermetabolites function as regulatory molecules.
DHP accumulation during the EMT program
In the liver, the pyrimidine degradation pathway is composed of three enzymes: DPYD, DPYS, and UPB1 (upper panel). The initial substrates of this pathway are the pyrimidines, uracil and thymine, and the final products are -alanine or 2-methyl--alanine. In the liver, DPYD products (DHU and DHT (DHPs)) are then further catabolized by DPYS, which is the only known enzyme to consume these metabolites. During EMT, DPYD is the only enzyme expressed from this pathway resulting in DHP accumulation in cells (lower panel). We previously demonstrated that the accumulation of DHP is essential for the EMT program.
×